Common somatic mutations in pancreatic adenocarcinoma (PAC)
The timing and frequency of acquired somatic mutations identified during the evolution from normal pancreatic tissue to invasive carcinoma has been elucidated through the study of pancreatic intraepithelial neoplasia (PanIn), the non-invasive precursor lesion of PAC ( Figure 1 ). [1] [2] [3] [4] [5] [6] [7] [8] PanIn is graded 1-3, with higher grades showing increasing numbers of acquired molecular changes and an association with progression to invasive malignancy. 9, 10 Activating KRAS mutations are seen in up to 90% of invasive PAC specimens, but are rarely found sporadically in normal pancreatic tissue. 11 Mouse models of PanIn have demonstrated a KRAS mutation to be one of the earliest genetic events occurring in the PanIn to PAC sequence. It is also a driver of the malignant phenotype and has a key role in the maintenance of PAC. 12 The p16/INK4A tumor suppressor gene is downregulated early in the PanIn to PAC progression model, with loss of function occurring early in 85-95% of sporadic pancreatic cancers. The SMAD4/DPC4 tumor suppressor gene is usually inactivated late in the development of PDAC, and is involved in the regulation of TGF-B-mediated cell growth and development while BRCA2 somatic mutations also occur late in the progression from PanIn to invasive PAC. More recently, whole-genome sequencing of 24 human pancreatic cancers has yielded a more comprehensive assessment of acquired genetic alterations in PAC. 13 An average of 63 mutations was identified per sample, with considerable interpatient heterogeneity. Of potential therapeutic relevance, however, is the observation that the genetic alterations identified had an effect on one or more of 12 common signaling pathways promoting cellular processes involved in the initiation and maintenance of PAC including cell cycle regulation, metabolism and DNA repair. 13 A subsequent publication reported on whole-genome exomic sequencing performed on the primary pancreatic tumor and several sites of metastases from seven patients. 14 The authors identified several distinct clonal populations both within the in the primary tumor and in the metastatic sites, suggesting that the genetic heterogeneity of pancreatic metastases reflects that within the primary tumor, with potentially multiple subclones arising from a single-parent clone. Mathematical modeling on the sequencing data estimated that the timeframe for development of the primary tumor was 410 years, with the subpopulation of clones with metastatic potential developing over a subsequent 5-6 years; a surprising observation given the ubiquitous 'late' clinical presentation of PAC. In collaboration with the same institution, investigation of chromosomal rearrangements in primary tumor and in several sites of metastases in 13 pancreatic cancer patients reported frequent genomic instability. 15 The investigators found evidence to support ongoing clonal adaption and evolution within developing metastases after dissemination. Despite this observation, for each patient over half of the genetic rearrangements identified were present both in the primary tumor and in all metastases, offering hope for potential exploitation of these driver mutations as therapeutic targets.
Several recent publications have focused on correlation of tumor SMAD4/DPC4 status with metastatic disease burden and patterns of disease spread. A rapid autopsy series performed on 76 patients with PAC compared results of DPC4 immunohistochemistry (IHC) in tumor samples taken from locally advanced cancers in patients without metastatic disease to those taken from patients with an extensive metastatic burden. Loss of staining for DPC4 was seen in 22% of localized cases but in 75% of metastatic cases. 16 A phase II trial of cetuximab, gemcitabine and oxaliplatin followed by chemoradiation with cetuximab in patients with localized PAC performed a retrospective assessment of DPC4 expression in pre-treatment biopsies and correlated with pattern of treatment failure. A total of 73% (11 of 15) patients with intact DPC4 expression had predominantly local disease progression, while 71% (10 of 14) patients with loss of DPC4 expression had distant progression of disease (P ¼ 0.016). 17 These collective observations suggest that the patients with retention of DPC4 expression may potentially benefit more from improved local control approaches with inclusion of combined chemotherapy and radiation over those with loss of DPC4 expression who are more likely to have a systemic pattern of disease. This hypothesis remains to be validated and several trials are in the planning phase to prospectively evaluate the concept.
Germline mutations associated with PAC
Approximately 7-10% of all PAC is estimated to occur in association with an inherited cancer predisposition syndrome. 18, 19 Although several inherited conditions are known to predispose to PAC, in up to 70% of familial cases no specific genetic abnormality is identified despite a significant family history. 20 Study of the National Familial Pancreas Tumor Registry, established to prospectively observe relatives of patients with PAC, 20 has shown that people with three first-degree relatives with PAC have a 32-fold increased risk of developing the disease. In those with two first-degree relatives the risk is increased by 6.4-fold, and those with one relative with PAC have a 4.6-fold increased risk of developing the disease. Notwithstanding the potential for shared environmental and lifestyle factors, this familial clustering of PAC cases in families is likely due in part to as yet unidentified genetic factors (Table 1) .
Peutz-Jeghers syndrome is an autosomal dominantly transmitted hereditary condition, characterised by hyperpigmentation of the buccal mucosae and lips, along with hamartomatous polyps of the gastro-intestinal tract. In all, 80% of the cases are due to a germline mutation in the STK11/LLDI gene, a condition associated with multiple cancers of the gastrointestinal tract, lung, breast and gynecological cancers. The increased risk of PAC is estimated at 132 times that of the general population. 21 Hereditary pancreatitis is a rare inherited condition characterised by recurrent episodes of acute pancreatitis. It arises due to a hereditary defect in the trypsinogen gene in the autosomal dominant form, or in the SPINK1 gene in the autosomal recessive form. It carries an estimated increased risk of PAC of 53-fold higher compared with the general population, with 30-40% of sufferers anticipated to develop invasive PAC by the age of 70 years. 22 In this population, PAC has been shown to occur significantly earlier in smokers compared with non-smokers. 23 Hereditary non-polyposis colorectal cancer is an autosomal dominant condition, resulting from a germline mutation in genes encoding for proteins responsible for DNA repair, including the MSH1/2, PMS1/2 and MSH6 genes. It carries an increased risk of colon, endometrial, ovarian, gastric, renal and urinary tract cancers as well as pancreatic and biliary cancers, although this risk has been difficult to quantify. 24 Familial atypical multiple mole and melanoma syndrome is an autosomal dominantly inherited condition resulting from a germline mutation in the p16/CDKN2A gene. It carries a 38-fold increased risk of developing PAC compared with the general population, along with an increased risk of melanoma, breast cancer, lung cancer and sarcoma. 25 Familial adenomatous polyposis is an autosomal dominant condition arising from a germline mutation in the APC tumor-suppressor gene carries a fourfold increased risk of PAC, along with an almost absolute risk of developing adenocarcinoma of the colon by age 40 years. Other associated cancers include thyroid, gastric, duodenal and ampullary carcinomas. 26 Of particular interest from a therapeutic viewpoint are germ line BRCA2 and BRCA1 mutations, which incur an increased risk of developing PAC estimated to be 2.5-3.5-fold higher than the background population. [27] [28] [29] The increased risk of malignancy in BRCA gene mutation carriers occurs due to the critical involvement of BRCA1 and BRCA2 in repair of DNA double-strand breaks by homologous recombination. In-vitro data have shown hypersensitivity of a BRCA2-deficient human pancreatic cell line, Capan-1, to DNA cross-linking agents mitomycin and cisplatin 30 and more recently to the novel agents, poly (ADP-ribose) polymerases (PARP) inhibitors. 31 PARP are a family of enzymes, two of which, PARP1 and 2, are key components of the DNA repair mechanism for cells with single-strand breaks and nucleoside base damage. 32 Inhibition of PARP in tumors with pre-existing defects in homologous recombination, such as BRCA1-or 2-deficient cells, leads to transformation of background single-strand breaks into double-strand breaks, which are cytotoxic in cells unable to repair double-strand breaks by homologous repair. 33 This effect of synthetic lethality provides the therapeutic rationale for the development of PARP inhibitors in BRCA1/2 mutation-associated malignancies, with considerable efficacy shown to date in phase II clinical trials of BRCA-mutant breast and ovarian cancer. 34, 35 A recent series from our group along with several anecdotal clinical reports, 36 indicate increased sensitivity to platinum chemotherapy and PARP inhibitors in patients with PAC arising on a background of known BRCA1/2 germline mutation. In our series of 15 patients, 4 patients received a PARP inhibitor alone or in combination with chemotherapy; 3 demonstrated an initial radiographic partial response whereas 1 patient had stable disease for 6 months. 37 Six patients received platinum-based chemotherapy first line for metastatic disease; five of those patients had a radiographic partial response. PARP inhibitors are currently undergoing prospective evaluation in both BRCA1/2 mutation associated and sporadic PAC.
The rapid development and refinement of sophisticated molecular techniques over the last decade has yielded a wealth of genomic data from both germline and tumor tissue, which requires complex and specialized statistical analysis to interpret and correlate with clinical data. Prognostic markers identify the likely disease course and so may indirectly influence choice of treatment, while predictive markers indicate the likelihood that an individual may benefit from a given therapy. Individualization of cancer therapy has long been a key goal of the oncology 
Hereditary pancreatitis
Trypsinogen/SPINK-1 Peutz-jaeger syndrome STK11/LLDI research community; the identification of epidermal growth factor receptor (EGFR) tyrosine kinase mutation in lung cancer and Her2 over expression in breast cancer as predictive biomarkers being two examples of the successful identification and validation of molecular markers with proven clinical utility. PAC poses a unique challenge in this area due to its genetic complexity 13 and the near ubiquitous finding of an activating KRAS mutation; an oncogene to which no effective inhibitor has yet been developed. Furthermore, the role of epithelial-mesechymal transition in the development of metastases and drug resistance in PAC has been increasingly recognized. Decreased expression of E-cadherin and increased expression of vimentin or fibronectin, all markers of epithelial-mesechymal transition, have been associated with reduced survival in patients with resected PAC, 38, 39 while in vitro data suggest that PAC cells that undergo epithelial-mesechymal transition develop stem cell-like properties and acquired drug resistance. 40, 41 Careful and independent prospective validation of all putative predictive or prognostic biomarkers, no matter how promising in retrospective or early phase trials, is essential before incorporation into clinical decision making.
Gemcitabine, fluorouracil and platinum pharmacogenomics
Gemcitabine is a key drug utilized in all stages of treating PAC. Gemcitabine exerts its cytotoxic effect predominantly through inhibition of DNA synthesis by the active metabolite 2 0 ,2 0 -difluorodeoxycytidine-5 0 -triphosphate. Incorporation of metabolite 2 0 ,2 0 -difluorodeoxycytidine-5 0 -triphosphate into the nucleotide chain halts elongation of the DNA strand following the addition of one base pair; the presence of this extra base pair before termination allows it to evade detection by DNA repair enzymes. 42 The metabolite 2 0 ,2 0 -difluorodeoxycytidine-5 0 -triphosphate also inhibits the repair activity of DNA polymerase. Gemcitabine requires transportation across the cellular membrane to allow intracellular phosphorylation resulting in the formation of this active metabolite. Two families of nucleoside transporters facilitate this, the sodium-dependent hENT1 and 2 equilibrative transporters, and to a lesser extent the sodium-independent hCNT 1-3 concentrative transporters. Once cellular uptake of the drug is achieved, phosphorylation is performed by the enzyme deoxycitidine kinase (DCK) resulting in active diphosphorylated and triphosphorylated forms. The enzyme cytidine deaminase (CDA) then metabolizes gemcitabine to the inactive form 2 0 2 0 -difluorodeoxyuridine, which is renally excreted. This dependence on cell membrane transporters and intracellular enzymes for activation and metabolism results in several key points at which the anti-tumor effect of gemcitabine may be altered by an increase or decrease in the activity of one of these components.
Several investigators have correlated tumor hENT levels with clinical outcomes. Immunohistochemistry for hENT1 protein was performed on 198 available tumor samples from patients treated on the prospective RTOG 9704 phase III trial. 43 All patients enrolled on this randomized phase III trial underwent surgical resection of localized PAC followed by postoperative chemoradiation, with a randomization to pre-and postradiation 5FU or gemcitabine chemotherapy. Tumor hENT1 protein expression was shown to correlate with overall survival (OS) in the 91 analyzable patients treated with gemcitabine, but not in patients treated with 5-fluorouracil (5-FU). 44 A study of hENT1 gene expression analysis in 83 patients treated in either the adjuvant or the metastatic setting with single-agent gemcitabine also reported significantly longer survival in patients with high hENT expression compared with those with low expression. Patients with lowest levels of hENT expression had median survival of 12.4 months, whereas those with the highest levels had median survival of 22.3 months (Po0.001), moreover in multivariate analysis hENT expression remained an independent predictive marker of survival. 45 These observations suggest a lack of clinical benefit to the use of gemcitabine in patients with low or absent hENT1, although this hypothesis requires prospective validation. A novel compound, gemcitabine-5 0 -elaidate, a fatty acid derivative of gemcitabine, does not require hENT1 for transportation across the cell membrane; it is metabolized to gemcitabine and elaidic acid intracellularly in blood and in tissue by esterase. This agent is currently undergoing prospective evaluation in a randomized phase II compared with single-agent gemcitabine 46 and as second-line therapy for advanced PAC in a multicenter non-randomized phase II trial, with recruitment limited to patients who have progression of disease as best response to front-line or adjuvant gemcitabine therapy and whose tumor demonstrates absent hENT1 staining by IHC. 47 In a study of 44 patients with advanced pancreatic cancer, reduced expression of dCK by IHC was shown to correlate with reduced OS and progression-free survival following gemcitabine-based chemotherapy (14.6 vs 21.7 months, Po0.04). 48 Sequencing of dCK gene in nine patient samples and 17 pancreatic cell lines with progression on gemcitabine, however, did not demonstrate any mutations, suggesting that acquired mutations altering the function of dCK enzyme are not a common acquired mechanism of resistance to gemcitabine. Epigenetic downregulation of dCK levels by promoter hypermethylation has been reported in cervical cancer cell lines with acquired gemcitabine resistance; the ability of the investigators to reverse this in vitro with the use of a demethylating agent suggests a potential future therapeutic strategy for gemcitabine-based combinations. 49 Severe and life threatenening toxicity with grade 4 neutropenia following gemcitabine administration has been reported in three patients homozygous for a genetic polymorphism in the CDA gene identified in a Japanese population; CDA 208G4A (Ala70Thr). These patients were found to have significantly reduced drug clearance secondary to reduced CDA activity, 50, 51 indicating that germline polymorphisms in the CDA gene leading to reduced enzyme activity may predict for reduced drug clearance and resultant severe toxicity following gemcitabine-based treatment. Evaluation of CDA activity in serum samples from 150 patients treated with gemcitabine alone or as part of a combination regimen for a variety of malignancies reported an association between reduced CDA activity and incidence of grade 3 or 4 toxicity. 52 All patients with a CDA value at or below 1 U mg À1 developed severe toxicity (7% of all patients), suggesting that CDA deficiency may predict for acute severe gemcitabine-related toxicity. Genotypic assessment in this European population identified no carriers of the CDA 208G4A polymorphism, no correlation between other polymorphisms CDA 435C4T and CDA 79 A4G and CDA activity or toxicity was seen. A recently published assessment of patients treated on the RTOG 9704 trial with gemcitabine or 5-FU, the CDA Lys27Gln polymorphism was found to be associated with increased risk of severe hematological toxicity but was not associated with OS in patients treated with gemcitabine. 53 A phase 1 study of prolonged (fixed dose rate) gemcitabine in 20 patients with advanced pancreatic cancer reported reduced OS and progression-free survival in patient with increased mononuclear cell CDA expression and activity (OS 8.5 vs 3.7 months for expression levels ovs 410, P ¼ 0.03). 54 This suggests that increased CDA expression may lead to gemcitabine resistance, although of note in this study the very small number of patients does not provide confidence in the observation. Furthermore, other investigators have not found a correlation between CDA and gemcitabine sensitivity in vivo. 55 Assessment of the value of CDA levels in predicting the patient toxicity or clinical benefit with gemcitabine therapy in prospective trials will be required before CDA activity may be considered part of routine clinical testing.
The OS benefit associated with the use of FOLFIRINOX in the PRODIGE/ACCORD II trial has provided further support for the use of 5FU-based combination chemotherapy regimens in PAC. 3 The pharmacogenetics of 5FU, capecitabine, platinum and irinotecan therapy have been extensively studied in colorectal cancer and to a lesser extent in PAC. In colorectal cancer, studies have indicated that decreased levels of intratumoural thymidylate synthetase (TS) protein and mRNA expression predict for response to 5-FU-based chemotherapy regimens, and are associated with increased survival compared with tumors with high TS expression. 56 These findings, however, await prospective validation in large clinical trials of colorectal cancer. Several retrospective studies have assessed the value of TS levels in predicting the benefit and toxicity to 5FU-based chemotherapy in PAC. In a retrospective study of 132 patients with resected PAC, staining by IHC of the primary tumor showed high intratumoral expression levels of TS in 63% of tumors; high TS expression was an independent predictor of mortality. 57 A significant reduction in risk of death in patients with high-TS-expressing tumors was seen in among patients who received adjuvant 5FU-based therapy (73 patients; response rate (RR) 0.37; 95% confidence intervals 0.16-0.86; Po0.0006), however, 5-FU-based adjuvant therapy did not influence survival among patients with low-TS-expressing pancreatic cancer. A further study looked at IHC for dihydropyrimidine dehydrogenase (DPD) in 68 resected pancreatic cancer specimens, 30 patients of whom had received postoperative adjuvant hepatic infusional 5FU. 58 In patients with high DPD levels, postoperative 5FU had no effect on survival, but in patients with low tumor DPD expression a survival benefit to the use of postoperative 5FU was seen (Po0.001). In patients with low DPD expression who received post-op 5FU, OS was better than in patients with high DPD expression who received the same treatment (Po0.04). No effect of DPD expression on survival was seen in patients who did not receive 5FU.
Identification of the importance of the nucleoside excision repair pathway in repair of platinum-induced DNA damage has led to the evauation of components of this pathway as potential biomarkers of resistance to therapy. Excision repair cross-complementing group 1 overexpression has been associated with resistance to oxaliplatin in colorectal cancer and to cisplatin in lung cancer and ovarian cancer, while polymorphisms in cross-complementing group 1 have been correlated with survival and resistance to platinum therapy. [59] [60] [61] In a retrospective study of patients with resected PAC, high cross-complementing group 1 levels were associated with reduced survival, while several investigators have identified ERCC1 overexpression as a negative predictor of outcome in patients with advanced PAC treated with platinum chemotherapy. 62, 63 Other potential biomarkers of response to platinum therapy include germline or somatic BRCA 1/2 mutations and ribonuceoside reductase subunit 1; in PAC.
Irinotecan pharmacogenomics have been studied mainly in patients with colorectal cancer, with the most clinically relevant finding being the association between reduced UDP-glucuronosyltransferase (UGT1A1) levels and irinotecan-induced toxicity including diarrhea and neutropenia. 64 Germline polymorphisms in the UGT1A1 gene, most commonly the UGT1A1*28 allele, leads to reduced expression of the enzyme, resulting decreased clearance of the active metabolite of irinotecan SN38 and so increased toxicity. The relevance of this finding in PAC therapy remains unclear. The major conclusion to date in PAC, as in other malignancies, is that collectively these biomarkers await prospective validation and at this time clinical decision making is not supported by any specific biomarker of disease or therapy.
Secreted Protein Acidic and Rich in Cysteine (SPARC)
The observation that primary pancreatic tumors are characterised by a dense stromal infiltrate and desmoplastic reaction has led to intensified research efforts to focus on targeting the stroma in a therapeutic sense and idenification of the genetic alterations of cells comprising the tumor micorenviroment. SPARC has long been recognized as a protein overexpressed in a variety of solid tumor malignancies, and is involved in multiple key cellular functions including cell invasion, proliferation and angiogenesis. 65, 66 Although pancreatic adenocarcinoma cells frequently show reduced expression of SPARC due to promotor hypermethylation, the surrounding stroma in contrast frequently demonstrates SPARC expression in peritumoral fibroblasts. 67 Expression of SPARC by components of the tumor stromal has been shown to have prognostic value in patients undergoing pancreatic resection for localized PAC. 68 Immunohistochemical analysis of SPARC expression in 299 resected tumor specimens demonstrated a correlation of SPARC expression in peritumoral fibroblasts with reduced OS (15 vs 30 months, Po0.01). SPARC expression in PAC adenocarcinoma cells in contrast did not correlate with survival. A smaller study of 49 patients treated with combined modality chemotherapy and radiation for locally advanced PAC evaluated SPARC expression by IHC on pretreatment tumor biopsies. 69 Although increased stellate cell expression of SPARC correlated with reduced survival (10.2 vs 7.6 months), peritumoral fibroblast expression did not, and adenocarcinoma cell expression of SPARC again had no prognostic significance. Other investigators have also shown a correlation between mRNA expression of SPARC in resected PAC tumor samples and survival, although microdissection to differentiate stromal from epithelial cell expression was not performed. 70 Nab-paclitaxel, an albumin-bound nanoparticle form of paclitaxel, is transported across the endothelial cell membrane by the process of transcytosis, an active transport mechanism. Albumin binds to the endothelial cell surface receptor gp60, which in turn activates caveolin-1 and results in invagination of the endothelial cell wall to form vesicular structures called caveolae, which trap plasma constituents. SPARC binds albumin with high affinity, and so in the interstitial space may increase the uptake of albumin-bound paclitaxel, thereby increasing intratumoral concentration of the drug; in vivo studies have supported this hypothesis. 71, 72 A phase I-II trial of gemcitabine in combination with nab-paclitaxel in 67 patients with advanced PAC did demonstrate that expression of SPARC by both PAC cells and surrounding stromal cells was predictive of response to nab-paclitaxel. Of the 44 patients treated at the maximum tolerated dose of nab-paclitaxel (125 mg m À2 ) in combination with gemcitabine (1000 mg m À2 ), median OS was 12.2 months (95% confidence intervals 8.9-17.8 months). The overall response rate to the combination was 46%, with three patients achieving a complete response. 73 An ongoing randomized phase III trial of gemcitabine with or without nab-paclitaxel will evaluate the combination in a larger, less highly selected patient population. 74 The significance of pancreatic tumor stroma as a potential therapeutic target is further supported by recently published data, which reported increased tumor delivery and enhanced efficacy of gemcitabine in the presence of the hedgehog pathway inhibitor IPI-926 in a mouse model of PAC. 75 The hedgehog-signaling pathway has a key role in the regulation of embryonic development, but is also constitutionally activated in several human cancers including PAC. In this preclinical model, the hedgehog pathway inhibition enhanced drug delivery to tumor cells by disrupting the desmplastic stroma and increasing tumor vascularity. The combination of gemcitabine with nabpaclitaxel and the hedgehog pathway inhibitor GDC-0449 is currently being evaluated in patients with advanced PAC in a multicenter phase II trial.
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S100A2
An assessment of 17 candidate biomarkers of outcome in 601 tumor samples from patients with operable or locally advanced PAC identified the calcium-binding protein S100A2 as an independent predictor of survival. Patients with high S100A2-expressing tumors had no benefit with pancreatectomy compared with those with stage III disease, while patients with S100A2-negative tumors had a survival benefit from pancreatectomy regardless of the lymph node or margin involvement. (survival 19.4 vs 8.8 months, hazard ratio 3.23, Po0.001).
77 Subsequent assessment of S100A2 expression on 150 specimens from patients treated on the prospective trial of adjuvant therapy RTOG 9704, however, did not identify S100A2 expression as an independent predictor of outcome on multivariate analysis, although the smaller sample size limited the power of this study. 78 Further prospective evaluation of prognostic and predictive significance of S100A2 is planned.
EGFR/KRAS
The marginal survival benefit seen with the addition of erlotinib to gemcitabine in the PA 3 phase III trial led to the approval of erlotinib for treatment of advanced PAC in 2005. 79 In lung cancer, the presence of an activating EGFR tyrosine kinase domain mutation has been shown to be predictive of response to EGFR tyrosine kinsase inhibitors, 80 however, in PAC, mutations in this area are rare. A total of 26% of the 569 patients enrolled on the initial phase III trial had tissue samples available for biomarker analysis. 81 In this group of 107 patients neither EGFR gene copy number nor KRAS mutation status were predictive of response to therapy or OS, although there was a non-significant trend toward increased survival in KRAS wild-type patients treated with erlotinib. The presence of grade II or greater skin rash was predictive of a survival benefit in patients treated with erlotinib. The small number of samples available limits the ability of this study to identify potential molecular markers of response to erlotinib. A recently completed phase III trial of 281 patients compared gemcitabine erlotinib followed by capecitabine to capecitabine/erlotinib followed by gemcitabine in patients with advanced PAC. Analysis of 208 available tissue samples reported an association on univariate analysis between KRAS mutation status and survival, no correlation was identified between EGFR status by FISH or IHC. None of the biomarkers examined correlated with the occurrence of skin rash. The currently enrolling RTOG 0848 trial of adjuvant gemcitabine with or without the addition of erlotinib and chemoradiation will prospectively evaluate potential molecular markers of response or resistance to anti-EGFR-based therapy. 82 
Summary
In conclusion, while PAC remains a challenging malignancy, significant progress has recently been made not only in elucidating the key genetic events involved in pancreatic tumorigenesis but also in identifying the clinical characteristics associated with these events. Further insights have been gained into the clonal evolution of both primary pancreatic tumors and metastatic sites, along with the important observation that despite the extent of genetic heterogeneity among pancreatic tumors, several key cell signaling pathways remain consistently aberrantly activated. The identification of inherited cancer predisposition syndromes in individuals with PAC and a personal or family history of associated malignancy offer the opportunity to develop screening modalities in high-risk families, and may potentially lead to the development of therapeutic strategies targeted at a genetically selected population. Recognition of the desmoplastic stromal component of PAC as a potential therapeutic target and modulator of response to therapy has been identified as a somewhat neglected area of research and possible therapeutic opportunity. The impact of germline polymorphisms and/or alteration in tumor expression of genes encoding cell membrane transporters and intracellular enzymes involved in the gemcitabine metabolism and activation is an area of ongoing research. Although initial results appear promising for prediction of benefit or toxicity, further prospective validation is required before these findings may impact on clinical practice. Several ongoing prospective trials of novel agents in PAC now incorporate pre-defined correlative studies evaluating the predictive and prognostic relevance of molecular markers identified from large-scale retrospective projects. This prospective validation of candidate biomarkers in independent randomised studies remains key to the development of individualized cancer therapy. A major future hope for PAC in this era of increasingly personalized medicine is the identification and validation of predictive and prognostic biomarkers in PAC, which may ultimately enable tailoring of therapy.
